Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$12,539 Mln
Revenue (TTM)
$4,413 Mln
Net Profit (TTM)
$0 Mln
ROE
0 %
ROCE
0.7 %
P/E Ratio
323.9
P/B Ratio
3.4
Industry P/E
27.93
EV/EBITDA
25
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$0.3
Face value
--
Shares outstanding
193,570,000
CFO
$3,462.76 Mln
EBITDA
$2,595.95 Mln
Net Profit
$1,896.67 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Incyte (INCY)
| -6.6 | 13.6 | -10.5 | 12.4 | -4.8 | -8.1 | -5.1 |
|
BSE Sensex*
| 4.3 | 2.5 | 8.3 | 9.9 | 14.5 | 21.6 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Incyte (INCY)
| 9.9 | -21.8 | 9.4 | -15.6 | -0.4 | 37.3 | -32.7 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Incyte (INCY)
|
64.5 | 12,539.5 | 4,413.2 | 21.3 | 7.2 | 0.6 | 323.9 | 3.4 |
| 20.2 | 4,803.3 | 459.4 | 206.8 | 25.6 | 68.3 | 24 | 13.1 | |
| 7.2 | 3,384.5 | 2,830.2 | -0.6 | 7.5 | -- | -- | 86.1 | |
| 104.4 | 5,207.2 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 97.9 | |
| 58.0 | 11,215.1 | 2,937.8 | 523.9 | 23.2 | 9.3 | 21.7 | 1.9 | |
| 33.0 | 6,235.7 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 76.1 | 8,038.2 | 685.5 | 132.9 | 15.6 | 20.1 | 65.9 | 11.8 | |
| 12.7 | 6,267.7 | 4,427.0 | 373.0 | -0.7 | 5.8 | 16.8 | 1.0 | |
| 85.0 | 4,171.6 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.7 | 2.4 | |
| 8.5 | 9,952.8 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.6 |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate... or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. Address: 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 Read more
CEO & Chairman
Mr. Herve Hoppenot
CEO & Chairman
Mr. Herve Hoppenot
Headquarters
Wilmington, DE
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Incyte Corp (INCY) stood at $ 7,470 Mln as on 31-Mar-25
The share price of Incyte Corp (INCY) is $64.51 (NASDAQ) as of 22-May-2025 16:00 EDT. Incyte Corp (INCY) has given a return of -4.85% in the last 3 years.
Incyte Corp (INCY) has a market capitalisation of $ 12,539 Mln as on 22-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Incyte Corp (INCY) is 3.42 times as on 22-May-2025, a 27% discount to its peers’ median range of 4.70 times.
The P/E ratio of Incyte Corp (INCY) is 323.90 times as on 22-May-2025, a 1060% premium to its peers’ median range of 27.93 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Incyte Corp (INCY) and enter the required number of quantities and click on buy to purchase the shares of Incyte Corp (INCY).
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. Address: 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
The CEO & director of Mr. Herve Hoppenot. is Incyte Corp (INCY), and CFO & Sr. VP is Mr. Herve Hoppenot.
There is no promoter pledging in Incyte Corp (INCY).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,126
|
|
|
988
|
|
|
751
|
|
|
647
|
|
|
639
|
|
|
510
|
|
|
475
|
|
|
422
|
|
|
349
|
| Incyte Corp. (INCY) | Ratios |
|---|---|
|
Return on equity(%)
|
0.62
|
|
Operating margin(%)
|
7.19
|
|
Net Margin(%)
|
0.48
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Incyte Corp (INCY) was $0 Mln.
$-0.27
(
